<DOC>
	<DOCNO>NCT01012362</DOCNO>
	<brief_summary>This Phase I study ; dose escalate combination pazopanib take daily ixabepilone administer day 1 3 week treatment course .</brief_summary>
	<brief_title>Study Pazopanib Ixabepilone Patients With Solid Tumors</brief_title>
	<detailed_description>Treatment ixabepilone give assign dose 3 hour intravenous infusion day 1 21 day cycle . Treatment pazopanib give assign dose mouth day , begin day 1 continue daily . Disease assessment do every 2 cycle ( 6 week ) treatment continue disease progression , unacceptable toxicity patient refusal .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Diagnosis advance nonhematologic solid tumor malignancy , include , limited breast , lung , colon , pancreatic , head neck , kidney sarcoma fail become intolerant standard therapy longer likely respond therapy Effective August 2011 version protocol , enrollment limit squamous cell carcinoma head neck ( refer section 1.4 rationale ) . Note : Patients primary diagnosis hepatocellular carcinoma eligible enrollment dose level 1 2 , provide meet inclusion/exclusion criterion maximum tolerate dose ( MTD ) pazopanib monotherapy patient hepatocellular cancer find 600 mg daily . Measureable evaluable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) . Prior systemic chemotherapy , immunotherapy , biological therapy allow ; however prior use either pazopanib ixabepilone alone combination allow . At least 14 day must elapse since 1 ) previous systemic therapy ( 28 day bevacizumab ) 1st dose study drug , 2 ) last dose radiation therapy surgery ( 28 day major surgery ) . Patient must recover acute toxic effect previous anticancer treatment prior study enrollment . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Adequate organ function within 14 day enrollment define : Absolute neutrophil count ( ANC ) &gt; 1.5 x 10^9/L Hemoglobin &gt; = 9 g/dL Platelets &gt; = 100 x 10^9/L Prothrombin time international normalized ratio , partial thromboplastin time ( PTT ) &lt; = 1.2 x upper limit normal ( ULN ) Total bilirubin &lt; = ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; = 2.5 x ULN Serum creatinine &lt; = 1.5 mg/dL Urine protein Creatinine Ratio &lt; 1 Total serum calcium &lt; 12.0 mg/dL Men woman childbearing potential must adhere protocol criterion prevent conception study Women pregnant nursing . Prior radiation &gt; =or = 30 % major bone marrow contain area ( pelvis , lumbar spine ) History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis Clinically significant gastrointestinal abnormality may increase risk GI bleeding may affect absorption investigational product History another malignancy must least 3 year diseasefree Presence uncontrolled infection Prolongation correct QT interval ( QTc ) &gt; 480 msecs History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease Class III IV congestive heart failure , define New York Heart Association ( NYHA ) Poorly control hypertension History cerebrovascular accident , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month Prior major surgery trauma within 28 day prior 1st dose study drug Evidence active bleeding bleed diathesis Known endobronchial lesion involvement large pulmonary vessel tumor Hemoptysis 6 week 1st dose study drug Neuropathy Grade 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Solid tumor malignancy</keyword>
	<keyword>breast cancer</keyword>
	<keyword>lung cancer</keyword>
	<keyword>colon cancer</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>head neck cancer</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>sarcoma</keyword>
	<keyword>hepatocellular cancer</keyword>
</DOC>